Long-term left ventricular assist devices in heart failure treatment
Authors:
V. Horváth; P. Němec; J. Ondrášek; H. Bedáňová; P. Fila; P. Pokorný; P. Pavlík; J. Slavík; R. Wagner
Authors‘ workplace:
Centrum kardiovaskulární a transplantační chirurgie, Brno
Published in:
Kardiol Rev Int Med 2016, 18(4): 253-257
Overview
Heart transplantation remains the gold standard therapy for patients with advanced heart failure. However, long-term left ventricular assist devices (LVAD) became the standard therapy because of the limited number of usable donor grafts and long waiting times. In this paper, we will summarise the history, evolution and function of LVADs. We will also present a review of complications and some specific clinical characteristics of patients with implanted LVAD. Three types of LVADs with continual flow are currently implanted in the Czech Republic: the second-generation LVAD with HeartMate II (Thoratec, USA) axial pump, third-generation LVAD with HeartWare HVAD (Heartware, USA) centrifugal pump, and as a part of clinical trials the newest third generation pump HeartMate III (Thoratec, USA), which is able to generate an artificial pulse. LVADs are already used in Czech Republic as a standard therapy for patients on the waiting list as a bridge to heart transplant. However, in future LVADs will be used for permanent implantation – destination therapy.
Keywords:
mechanical circulatory support – left ventricular assist devices
Sources
1. Lund LH, Edwards LB, Kucheryavaya AY et al. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report 2013; focus theme: age. J Heart Lung Transplant 2013; 32(10): 951– 964. doi: 10.1016/ j.healun.2013.08.006.
2. Englert JA, Davis JA, Krim SR. Mechanical circulatory support for the failing heart: continuous-flow left ventricular assist devices. Ochsner J 2016; 16(3): 263– 269.
3. Goldsmith MF. First implant of portable heart-assist device. JAMA 1991; 265(22): 2930– 2933.
4. Birks EJ, Tansley PD, Hardy J et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006; 355(18): 1873– 1884.
5. Miller LW, Pagani FD, Russell SD et al. HeartMate II Clinical Investigators. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357(9): 885– 896.
6. Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term use of a left ventricular assist device for end stage heart failure. N Engl J Med 2001; 345(20): 1435– 1443.
7. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart silure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016, 18(8): 891– 975. doi: 10.1002/ ejhf.592.
8. Lietz K, Long JW, Kfoury AG et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007; 116(5): 497– 505.
9. Starling RC, Naka Y, Boyle AJ et al. Results of the post U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011; 57(19): 1890– 1898. doi: 10.1016/ j.jacc.2010.10.062.
10. Kirklin JK, Naftel DC, Kormos RL et al. Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant 2010; 29(1): 1– 10. doi: 10.1016/ j.healun.2009.10.009.
11. Holman WL, Pae WE, Teutenberg JJ et al. INTERMACS: interval analysis of registry data. J Am Coll Surg 2009; 208(5): 755– 761, discussion 761– 762. doi: 10.1016/ j.jamcollsurg.2008.11.016.
12. Stevenson LW, Pagani FD, Young JB et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28(6): 535– 541. doi: 10.1016/ j.healun. 2009.02.015.
13. Estep JD, Trachtenberg BH, Loza LP et al. Continuous flow left ventricular assist devices: shared care goals of monitoring and treating patients. Methodist Debakey Cardiovasc J 2015; 11(1): 33– 44. doi: 10.14797/ mdcj-11-1-33.
14. Slaughter MS, Pagani FD, Rogers JG et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010; 29 (4 Suppl): S1– S38. doi: 10.1016/ j.healun.2010.01.011.
15. Aissaoui N, Morshuis M, Schoenbrodt M et al. Temporary right ventricular mechanical circulatory support for the management of right ventricular failure in critically ill patients. J Thorac Cardiovasc Surg 2013; 146(1): 186– 191.
16. Netuka I, Malý J, Szarszoi O et al. Technique of implantation and experience with temporary mechanical cardiac support in right ventricular failure. Rozhl Chir 2011; 90(2): 88– 94.
17. Atluri P, Goldstone AB, Fairman AS et al. Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thorac Surg 2013; 96(3): 857– 863, discussion 863– 864. doi: 10.1016/ j.athoracsur.2013.03.099.
18. Beyersdorf F, Schlensak C, Berchtold-Herz M et al. Regression of “fixed” pulmonary vascular resistance in heart transplant candidates after unloading with ventricular assist devices. J Thorac Cardiovasc Surg 2010; 140(4): 747– 749. doi: 10.1016/ j.jtcvs.2010.05.042.
19. Etz CD, Welp HA, Tjan TD et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 2007; 83(5): 1697– 1705.
20. Zimpfer D, Zrunek P, Roethy W et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 2007; 133(3): 689– 695.
21. Morgan JA, Paone G, Nemeh HW et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2012; 31(7): 715– 718. doi: 10.1016/ j.healun.2012.02.015.
22. Stern DR, Kazam J, Edwards P et al. Increas-ed incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg 2010; 25(3): 352– 356. doi: 10.1111/ j. 1540-8191.2010.01025.x.
23. Hasin T, Marmor Y, Kremers W et al. Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol 2013; 61(2): 153– 163. doi: 10.1016/ j.jacc.2012.09.041.
24. Crow S, John R, Boyle A et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009; 137(1): 208– 215. doi: 10.1016/ j.jtcvs.2008.07.032.
25. Geisen U, Heilmann C, Beyersdorf F et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33(4): 679– 684. doi: 10.1016/ j.ejcts.2007.12.047.
26. Meyer AL, Malehsa D, Budde U et al. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2014; 2(2): 141– 145. doi: 10.1016/ j.jchf.2013.10.008.
27. Goldstein DJ, Naftel D, Holman W et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant 2012; 31(11): 1151– 1157. doi: 10.1016/ j.healun.2012.05.004.
28. Kirklin JK, Naftel DC, Kormos RL et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 2013; 32(2): 141– 156. doi: 10.1016/ j.healun.2012.12.004.
29. Kato TS, Schulze PC, Yang J et al. Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transplant 2012; 31(1): 1– 8. doi: 10.1016/ j.healun.2011.08.014.
30. Pagani FD, Miller LW, Russell SD et al. HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54(4): 312– 321. doi: 10.1016/ j.jacc.2009.03.055.
31. Menon AK, Götzenich A, Sassmannshausen H et al. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg 2012; 42(2): 319– 323, discussion 323. doi: 10.1093/ ejcts/ ezr312.
32. Moazami N, Milano CA, John R et al. Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg 2013; 95(2): 500– 505. doi: 10.1016/ j.athoracsur.2012.09.011.
33. Nishimura M, Ogiwara M, Ishikawa M. Fifteen-month circulatory support for sustained ventricularfibrillation by left ventricular assist device. J Thorac Cardiovasc Surg 2003; 126(4): 1190– 1192.
33. Oz MC, Rose EA, Slater J et al. Malignant ventricular arrhythmias are well tolerated in patients receiving long-term left ventricular assist devices. J Am Coll Cardiol 1994; 24(7): 1688– 1691.
34. Ziv O, Dizon J, Thosani A et al. Effects of left ventricular assist device therapy on ventricular arrhythmias J Am Coll Cardiol 2005; 45(9): 1428– 1434.
35. Cantillon DJ, Saliba WI, Wazni OM et al. Low cardiac output associated with ventricular tachyarrhythmias in continuous-flow LVAD recipients with a concomitant ICD (LoCo VT Study). J Heart Lung Transplant 2014; 33(3): 318– 320. doi: 10.1016/ j.healun.2013.11.005.
36. Garan AR, Yuzefpolskaya M, Colombo PC et al. Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? J Am Coll Cardiol 2013; 61(25): 2542– 2450. doi: 10.1016/ j.jacc.2013.04.020.
37. John R, Naka Y, Smedira NG et al. Continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg 2011; 92(4): 1406– 1413, discussion 1413. doi: 10.1016/ j.athoracsur.2011.05.080.
38. Horvath V, Ondrasek J, Fila P et al. Minimally invasive implantation of left ventricular assist device HeartWare HVAD. Cor Vasa 2015; 57(2): e70– e74.
39. Puehler T, Ensminger S, Schoenbrodt M et al. Mechanical circulatory support devices as destination therapy – current evidence. Ann Cardiothorac Surg 2014; 3(5): 513– 524. doi: 10.3978/ j.issn.2225-319X.2014.08.20.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2016 Issue 4
Most read in this issue
- Long-term left ventricular assist devices in heart failure treatment
-
Comment on ESC/CSC Guidelines
Diagnosis of heart failure - Treatment of hypertension in older patients
- Lipertance® – two problems, one solution